Top-News

Progenics Pharmaceuticals News

Keine aktuellen Kursdaten verfügbar
WKN: 910678
ISIN: US7431871067
US-Symbol: PGNX
Typ: Aktie

Progenics Pharmaceuticals News

17.06.20 - PR Newswire
Independent Bank Group Set to Join S&P SmallCap 600
Independent Bank Group Set to Join S&P SmallCap 600 PR Newswire
27.05.20 - PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc. PR Newswire
08.05.20 - PR Newswire
Progenics Class Action: Halper Sadeh LLP Announces Filing Of Shareholder Class Action Lawsuit Against Progenics Pharmaceuticals, Inc.; Investors Are Encouraged To Contact The Firm
Progenics Class Action: Halper Sadeh LLP Announces Filing Of Shareholder Class Action Lawsuit Against Progenics Pharmaceuticals, Inc.; Investors Are Encouraged To Contact ...
23.04.20 - PR Newswire
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Progenics Pharmaceuticals, Inc. (PGNX)
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Progenics Pharmaceuticals, Inc. (PGNX) PR Newswire
11.12.19 - PR Newswire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Regarding the November 12, 2019 Registration Statement of Progenics Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Regarding the November 12, 2019 Registration Statement of Progenics Pharmaceuticals, Inc. ...
04.10.19 - PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc. PR Newswire
03.10.19 - PR Newswire
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of the Following Merger
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of the Following Merger PR Newswire
03.10.19 - PR Newswire
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Progenics Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Lantheus Holdings, Inc.
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Progenics Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Lantheus Holdings, Inc. PR Newswire
02.10.19 - PR Newswire
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on Behalf of Progenics Shareholders and Encourages Progenics Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on Behalf of Progenics Shareholders and Encourages ...
02.10.19 - PR Newswire
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Progenics Pharmaceuticals, Inc.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Progenics Pharmaceuticals, Inc. PR Newswire
12.08.19 - PR Newswire
Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results
Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results Progenics' Self-​Proclaimed "Master[s] of Commercialization" ...
22.07.19 - PR Newswire
Velan Announces Progenics Pharmaceuticals Stockholders Support its Campaign for Change at Progenics' 2019 Annual Meeting
Velan Announces Progenics Pharmaceuticals Stockholders Support its Campaign for Change at Progenics' 2019 Annual Meeting Final Voting Results Confirm that Approximately ...
17.07.19 - PR Newswire
Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets
Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets PR Newswire
08.07.19 - PR Newswire
Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch
Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch Agrees with ISS that ...
01.07.19 - PR Newswire
Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch
Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch Agrees with ISS that the ...
28.06.19 - PR Newswire
ISS Supports Velan's Call for Change by Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch
ISS Supports Velan's Call for Change by Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch ISS Believes ...
25.06.19 - PR Newswire
Velan Releases Presentation Reiterating the Facts and Setting The Record Straight for Progenics Pharmaceuticals' Stockholders
Velan Releases Presentation Reiterating the Facts and Setting The Record Straight for Progenics Pharmaceuticals' Stockholders Highlights How the Board is Distorting the Truth, ...
20.06.19 - PR Newswire
Velan Releases Detailed Presentation on Progenics Pharmaceuticals
Velan Releases Detailed Presentation on Progenics Pharmaceuticals Details the Persistent Performance, Execution, Governance and Transparency Shortcomings that Have Led to ...
20.06.19 - PR Newswire
Velan Calls on Progenics Pharmaceuticals' Board to Back Up Recent Claims
Velan Calls on Progenics Pharmaceuticals' Board to Back Up Recent Claims Actual Stockholders, the True Owners of the Company, Deserve Answers and Clarity Urges ...
11.06.19 - PR Newswire
Velan Capital Sends Letter to Stockholders Calling Out Progenics Pharmaceuticals' Board for Unnecessarily Diluting Stockholders to Support Outsized And Undeserved Compensation
Velan Capital Sends Letter to Stockholders Calling Out Progenics Pharmaceuticals' Board for Unnecessarily Diluting Stockholders to Support Outsized And Undeserved ...

Newssuche

Videos

newspaper
24.04.24
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »